Additional file 3: of CD38 is methylated in prostate cancer and regulates extracellular NAD+
- Jack Mottahedeh (5119268)
- Michael Haffner (5779562)
- Tristan Grogan (628047)
- Takao Hashimoto (662481)
- Preston Crowell (5779565)
- Himisha Beltran (5779568)
- Andrea Sboner (180596)
- Rohan Bareja (5779571)
- David Esopi (4347547)
- William Isaacs (4458526)
- Srinivasan Yegnasubramanian (27577)
- Matthew Rettig (146731)
- David Elashoff (195366)
- Elizabeth Platz (3624092)
- Angelo De Marzo (200674)
- Michael Teitell (5779574)
- Andrew Goldstein (5779577)
Publication date
September 2018
DOIAbstract
Re-expression of CD38 in prostate cancer cell lines after treatment with DNA methyltransferase inhibitor. Prostate cancer cell lines CWR22rv1, DU145, LNCaP, and LAPC4 were treated with 100 nM, 500 nM 5-aza-2′-deoxycytidine (decitabine, DAC), or solvent (DMSO) for 4 days. Expression of CD38 was determined by quantitative real-time PCR. Note that a modest re-expression of CD38 was observed in two (CWR22rv1, LAPC4) out of four cell lines. (TIF 124 kb
Add to ORKG